Related Experiment Video
Updated: May 29, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Predictors of response to cardiac resynchronization therapy in patients with a non-left bundle branch block
John Rickard1, Mohamed Bassiouny, Edmond M Cronin
1Heart and Vascular Institute Cleveland Clinic, Ohio, USA. rickarj2@ccf.org
Insights
Patients with non-left bundle branch block (LBBB) may benefit from cardiac resynchronization therapy (CRT). A wider QRS duration in these patients predicts better reverse ventricular remodeling and improved long-term outcomes with CRT.
Area of Science:
- Cardiology
- Electrophysiology
- Heart Failure Management
Background:
- Cardiac resynchronization therapy (CRT) is effective for heart failure, primarily in patients with left bundle branch block (LBBB).
- The benefits of CRT in patients without LBBB (non-LBBB morphologies) are less understood.
- Identifying predictors of CRT response in non-LBBB patients is crucial for optimizing treatment.
Purpose of the Study:
- To investigate the characteristics associated with CRT response in patients with non-LBBB morphologies.
- To determine the relationship between baseline QRS duration and long-term outcomes in this patient group.
Main Methods:
- Retrospective analysis of 99 patients with advanced heart failure, LVEF ≤35%, and QRS duration ≥120 ms, excluding LBBB.
- Response defined as ≥10% decrease in left ventricular end-systolic volume.
- Multivariate models used to identify predictors of response and long-term outcomes.
Main Results:
- 52.5% of patients with non-LBBB morphologies responded to CRT.
- Wider QRS duration was significantly associated with CRT response (OR 1.23 per 10 ms).
- Wider QRS duration was inversely associated with poor long-term outcomes (HR 0.79 per 10 ms).
Conclusions:
- In patients with advanced heart failure and non-LBBB morphologies, a wider QRS duration is a key predictor of CRT effectiveness.
- Baseline QRS duration influences reverse ventricular remodeling and long-term prognosis in non-LBBB CRT recipients.
Abstract:
Patients with non-left bundle branch block (LBBB) morphologies are thought to derive less benefit from cardiac resynchronization therapy (CRT) than those with LBBB. However, some patients do exhibit improvement. The characteristics associated with a response to CRT in patients with non-LBBB morphologies are unknown. Clinical, electrocardiographic, and echocardiographic data were collected from 850 consecutive patients presenting for a new CRT device. For inclusion, all patients had a left ventricular ejection fraction of ≤35%, a QRS duration of ≥120 ms, and baseline and follow-up echocardiograms available. Patients with a paced rhythm or LBBB were excluded. The response was defined as an absolute decrease in left ventricular end-systolic volume of ≥10% from baseline. Multivariate models were constructed to identify variables significantly associated with the response and long-term outcomes. A total of 99 patients met the inclusion criteria. Of these 99 patients, 22 had right bundle branch block and 77 had nonspecific intraventricular conduction delay; 52.5% met the criteria for response. On multivariate analysis, the QRS duration was the only variable significantly associated with the response (odds ratio per 10-ms increase 1.23, 95% confidence interval 1.01 to 1.52, p = 0.048). During a mean follow-up of 5.4 ± 0.9 years, 65 patients died or underwent heart transplant or left ventricular assist device placement. On multivariate analysis, the QRS duration was inversely associated with poor long-term outcomes (hazard ratio per 10-ms increase 0.79, 95% confidence interval 0.66 to 0.94, p = 0.005). In patients with advanced heart failure and non-LBBB morphologies, a wider baseline QRS duration is an important determinant of enhanced reverse ventricular remodeling and improved long-term outcomes after CRT.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure Drugs: β-Blockers
Cardiomyopathy II: Dilated Cardiomyopathy
